clinical trials

News

MSD preparing to take on Beyfortus with RSV antibody

New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting

News

Wave Life Sciences president and CEO Paul Bolno

Wave surges on first RNA editing data in humans

Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD).

News

MeiraGTx plans to take Parkinson's gene therapy into phase 3

Armed with data from a small phase 1/2 bridging study, MeiraGTx is preparing to take its gene therapy for Parkinson's disease into a pivotal trial.

R&D

Forecasting considerations throughout the pharmaceutical pro...

Forecasting is a critical component of product management, especially in the pharmaceutical industry, where it plays a vital role throughout the product lifecycle.

News

Transgene cervical cancer shot misses the mark in phase 2

Transgene's therapeutic vaccine for cervical and anogenital cancers has failed a phase 2 trial, but an efficacy signal warrants further study

News

GSK asthma hope depemokimab works in second indication

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

MSD preparing to take on Beyfortus with RSV antibody

Wave surges on first RNA editing data in humans

MeiraGTx plans to take Parkinson's gene therapy into phase 3

Forecasting considerations throughout the pharmaceutical pro...

Transgene cervical cancer shot misses the mark in phase 2

GSK asthma hope depemokimab works in second indication

Gilead strikes again, penning $5bn deal to buy Tubulis

Using AI-driven synthetic personas to take your insights fur...

clinical trials

Editor's Picks